ALPMY - Astellas Twist Bioscience team up for discovering antibodies for multiple targets
- Twist Bioscience ( NASDAQ: TWST ) and Astellas Pharma ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) are collaborating to discover antibodies against multiple targets of interest to develop therapies for patients with diseases lacking treatment options.
- Under the agreement, Twist will conduct antibody discovery activities against multiple targets identified by Astellas. In addition to an upfront payment and project specific research fees, Twist will be eligible to receive up to $11M per product linked to specific clinical and commercial milestones, plus royalties on sales.
- Astellas will be responsible for the development, manufacturing and commercialization of any such products, the companies added.
- "This second collaboration with Astellas demonstrates the power of our antibody discovery capabilities. The depth and breadth of our Library of Libraries enables highly potent antibodies, often missed using other technologies, to be identified across multiple potential therapeutic areas," said Twist Co-Founder and CEO Emily Leproust.
For further details see:
Astellas, Twist Bioscience team up for discovering antibodies for multiple targets